Goldman Sachs Group Inc. Sells 94,837 Shares of Tenaya Therapeutics, Inc. $TNYA

Goldman Sachs Group Inc. trimmed its position in Tenaya Therapeutics, Inc. (NASDAQ:TNYA) by 31.0% in the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 211,171 shares of the company’s stock after selling 94,837 shares during the period. Goldman Sachs Group Inc. owned approximately 0.13% of Tenaya Therapeutics worth $120,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in TNYA. Deutsche Bank AG increased its position in Tenaya Therapeutics by 304.1% in the 4th quarter. Deutsche Bank AG now owns 129,319 shares of the company’s stock valued at $185,000 after buying an additional 97,318 shares in the last quarter. Nuveen Asset Management LLC boosted its stake in Tenaya Therapeutics by 25.2% during the 4th quarter. Nuveen Asset Management LLC now owns 345,192 shares of the company’s stock valued at $494,000 after purchasing an additional 69,377 shares during the last quarter. Wealth Enhancement Advisory Services LLC acquired a new position in Tenaya Therapeutics during the 1st quarter valued at about $33,000. CWM LLC boosted its stake in Tenaya Therapeutics by 14,231.7% during the 1st quarter. CWM LLC now owns 71,945 shares of the company’s stock valued at $41,000 after purchasing an additional 71,443 shares during the last quarter. Finally, Virtu Financial LLC boosted its stake in Tenaya Therapeutics by 29.4% during the 1st quarter. Virtu Financial LLC now owns 135,502 shares of the company’s stock valued at $77,000 after purchasing an additional 30,790 shares during the last quarter. 90.54% of the stock is owned by institutional investors.

Tenaya Therapeutics Stock Down 4.8%

Shares of NASDAQ TNYA opened at $1.58 on Tuesday. Tenaya Therapeutics, Inc. has a twelve month low of $0.36 and a twelve month high of $4.01. The stock’s 50 day moving average price is $1.08 and its 200-day moving average price is $0.74. The company has a market capitalization of $257.50 million, a PE ratio of -1.65 and a beta of 3.07.

Tenaya Therapeutics (NASDAQ:TNYA) last posted its quarterly earnings data on Wednesday, August 6th. The company reported ($0.14) EPS for the quarter, beating the consensus estimate of ($0.20) by $0.06. As a group, research analysts expect that Tenaya Therapeutics, Inc. will post -1.35 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities analysts have issued reports on TNYA shares. Wall Street Zen upgraded Tenaya Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, August 9th. Chardan Capital reiterated a “buy” rating and set a $9.00 price target on shares of Tenaya Therapeutics in a research note on Thursday, August 7th. Finally, HC Wainwright reiterated a “buy” rating and set a $5.00 price target on shares of Tenaya Therapeutics in a research note on Tuesday, September 2nd. Six analysts have rated the stock with a Buy rating, According to MarketBeat, the stock currently has an average rating of “Buy” and a consensus target price of $6.25.

Tenaya Therapeutics Company Profile

Tenaya Therapeutics, Inc, a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. It develops its products through gene editing, cellular regeneration, and gene addition. The company is developing TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy which is in phase 1 clinical trial; TN-301, a small molecule for heart failure with preserved ejection fraction which is in phase 1 clinical trial; and TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy which is in preclinical stage.